Sponsor content
40 result(s) found, displaying 21 to 30
-
Australian public assessment report (AusPar)AusPAR for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) as booster dose for active immunisation to prevent COVID-19
-
Prescription medicine decision summaryapproved to prevent coronavirus disease 2019 (COVID-19)
-
Prescription medicine registrationActive ingredients: elasomeran, davesomeran.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX (elasomeran) COVID-19 VACCINE 0.2 mg/mL suspension for injection vial.
-
Australian public assessment report (AusPar)AusPAR for SPIKEVAX COVID-19 VACCINE (elasomeran) as booster in 12 to 17 years of age for prevention of COVID-19
-
Designation or determinationProvisional determination
-
Australian public assessment report (AusPar)SPIKEVAX BIVALENT ORIGINAL/OMICRON - (elasomeran and imelasomer) for prevention of COVID-19
-
Prescription medicine decision summarySpikevax Bivalent Original/Omicron (elasomeran and imelasomeran) was approved for the prevention of COVID-19.
-
Prescription medicine registrationActive ingredients: elasomeran, imelasomeran.
-
Australian public assessment report (AusPar)Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older